Core Viewpoint - The growth path of international giants in the biopharmaceutical industry is clear, achieved through mergers, integration, and innovative research and development, leading to comprehensive coverage of the upstream industry chain from consumables, equipment to services. This model is feasible for Chinese companies, but it requires time to mature [1] Group 1 - The chairman of Aopumai, Xiao Zhihua, emphasized the importance of mergers and acquisitions in the growth strategy of international giants [1] - The biopharmaceutical industry in China has the potential to develop similar companies, but it will take time for them to establish themselves [1]